Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 3

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 3
---
Except as described above, no other changes have been made to the Original Report and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Report or the Proxy Statement. This Amendment does not reflect events that may have occurred subsequent to the date of filing of the Original Report or the Proxy Statement. Accordingly, this Amendment should be read in conjunction with the Original Report and the Proxy Statement.

| PART III  |     |                                                                                                |     |    |
| ITEM 10.  |     | DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE                                        |     |  3 |
| ITEM 11.  |     | EXECUTIVE COMPENSATION                                                                         |     |  9 |
| ITEM 12.  |     | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |     | 41 |
| ITEM 13.  |     | CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTORS INDEPENDENCE                         |     | 42 |
| ITEM 14.  |     | PRINCIPAL ACCOUNTANT FEES AND SERVICES                                                         |     | 43 |
| PART IV   |     |                                                                                                |     |    |
| ITEM 15.  |     | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES                                                     |     | 44 |
| SIGNATURE |     |                                                                                                |     | 45 |

# PART III

## ITEM 10.

## DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

#### Corporate Code of Conduct
All of the Company’s employees, officers, and directors are subject to the Company’s Corporate Code of Conduct, which is available on the Company’s website at www.arrowheadpharma.com. The code meets the requirements of Nasdaq Marketplace Rules, as well as the code of ethics requirements of the Securities and Exchange Commission (“SEC”). We intend to disclose future amendments to certain provisions of the Corporate Code of Conduct, and waivers of the Corporate Code of Conduct granted to officers and directors, on the Company’s website within four business days following the date of the amendment or waiver.

#### Insider Trading Policy
Our insider trading policy governs the purchase, sale and other transactions in our securities by our directors, officers and employees, and other covered persons, as well as the Company itself, and is designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing